Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor-a and interleukin-6) and hepatokines, and decreased levels of adiponectin, an anti-inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.
Summary
Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease (NAFLD) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor-a and interleukin-6) and hepatokines, and decreased levels of adiponectin, an anti-inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.
What's already known about this topic?
• Patients with psoriasis have an increased risk of nonalcoholic fatty liver disease and increased levels of proinflammatory adipokines and hepatokines.
What does this study add?
• This article explores the possible role of chronic, low-grade inflammation in the pathogenesis of nonalcoholic fatty liver disease.
• All patients with psoriasis should be screened for nonalcoholic fatty liver disease.
Psoriasis, a complex, immune-mediated condition, affects approximately 3% of the population in the U.S.A., affecting both sexes equally. 1 The worldwide prevalence of psoriasis varies considerably; a high prevalence of approximately 11% has been reported in Norway, compared with lower prevalences of 1Á3% and 0Á1-2% in the U.K. and China, respectively. 2 Although the pathogenesis of psoriasis is not completely clear, genetic, immunological and environmental factors are thought to be involved. 3 Psoriatic disease most often affects the skin; however, patients with psoriasis are at higher risk for development of multiple extracutaneous systemic manifestations and comorbid conditions, including psoriatic arthritis (PsA), cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), obesity and metabolic syndrome (MetS; Fig. 1 ); obesity and MetS are also known risk factors for NAFLD. [4] [5] [6] [7] [8] Furthermore, rates of comorbidity, prevalence of specific comorbid conditions and cause-specific mortality increase with psoriasis severity. 9, 10 fibrosis (Tables 1 and 2) . 11, 12 Patients with NAFLD are at increased risk for diabetes and cardiovascular disease; hypertension, sleep apnoea and vitamin D deficiency have been associated with the progression of NAFLD. [13] [14] [15] Patients with NASH are at risk for progression to advanced liver diseases, such as cirrhosis and hepatocellular carcinoma. 16, 17 In the U.S.A., the prevalence of NAFLD is estimated at 19Á0%. 18 Dermatologists need to recognize the link between psoriasis and NAFLD. Understanding this association enables proper assessment of psoriasis and informed decision making about which pharmacological treatments to prescribe (e.g. those without hepatotoxic or lipid-elevating potential). Furthermore, dermatologists can engage in appropriate patient education and consultation with a hepatologist if warranted.
The evidence: a link between psoriasis and nonalcoholic fatty liver disease Insulin resistance and MetS are very common in both psoriasis and NAFLD. [19] [20] [21] [22] The release of inflammatory adipokines associated with these comorbidities drives further low-grade inflammation, leading to a vicious cycle that causes worsening of liver damage and progression of NAFLD. 23 This inflammation may also drive the progression of psoriasis. 22, 24 See Table 3 for evidence supporting the association between psoriasis and NAFLD. Initial case reports documented psoriasis in three patients with NASH, 24 a patient with NASH and comorbid type 2 diabetes and psoriasis, 25 and a patient with psoriasis, increased insulin resistance markers, elevated liver enzymes and NASH. 26 Thereafter, investigations into a possible link between psoriasis and NAFLD ensued, and in each controlled retrospective or prospective study, the prevalence of NAFLD was significantly higher in patients with psoriasis than in healthy or matched controls (17-66% vs. 8-35%, respectively). [27] [28] [29] [30] [31] [32] Additionally, patients with psoriasis were at significantly increased risk for NAFLD than controls (odds ratio 2Á15) in a systematic review and meta-analysis of seven case-controlled studies, six of which assessed risk of NAFLD among individuals with and without psoriasis. 32 In several studies, the presence and severity of psoriasis correlated with the prevalence, severity, and NAFLD risk (Fig. 2) . 27, 28, [31] [32] [33] [34] Compared with patients with psoriasis alone, patients with psoriasis and NAFLD had more severe psoriasis, 27, 28 and NAFLD was a significant predictor of higher Psoriasis Area and Severity Index (PASI) scores. 27 Conversely, PASI was a significant and independent predictor of NAFLD grade. 31 Additionally, patients with mild-to-moderate psoriasis were less likely than those with moderate-to-severe psoriasis to have comorbid liver disease. 27, [31] [32] [33] [34] Furthermore, patients with psoriasis and NAFLD were significantly more likely than patients with NAFLD alone to have severe NAFLD, including steatosis, fibrosis and NASH. 28, 35 Although both psoriasis and NAFLD are associated with metabolic conditions, such as MetS, insulin resistance and obesity, it was unclear whether psoriasis could be independently associated with NAFLD. Recently, two studies demonstrated that psoriasis was a significant predictor of liver disease, 30, 36 and in elderly patients, psoriasis was independently associated with a 70% increased likelihood for developing NAFLD. 29 When patients with and without psoriasis were compared, NAFLD Fibrosis Scores (À1Á57 vs. À3Á10; P ≤ 0Á0001), presence of steatosis (44Á3% vs. 34Á0%; P = 0Á02) and presence of advanced liver fibrosis (8Á1% vs. 3Á6%; P = 0Á05) were significantly higher in patients with psoriasis; drug exposure was not evaluated. 30, 36 Furthermore, psoriasis is a significant predictor of NAFLD severity and the likelihood of having advanced NAFLD was increased by approximately 60% when psoriasis was present. 29 five patients with psoriasis and NAFLD who underwent biopsy had NASH, 35 and others, in which surrogate serum markers of fibrosis [C-reactive protein (CRP) and transaminases] were increased. 27, 28 Drugs that increase liver toxicity, such as methotrexate, can be another 'hit' towards progression of NAFLD in a susceptible liver. Moreover, MetS and NASH are associated with several risk factors for methotrexate-mediated liver damage, such as obesity, diabetes and hyperlipidaemia.
The common thread: low-grade chronic inflammation
Chronic, low-grade inflammation appears to be the common aetiological factor between psoriasis and NAFLD, and comorbidities such as MetS. 6 Adipose tissue acts as an endocrine organ, producing adipocytokines or adipokines, 38, 39 which play important roles in psoriasis and NAFLD pathogenesis (Fig. 3) . 6, [40] [41] [42] These include leptin, adiponectin and resistin, which are important for energy balance, lipid and glucose metabolism, insulin sensitivity, blood pressure and angiogenesis, in addition to tumour necrosis factor-a (TNF-a) and interleukin-6 (IL-6), which are vital to the inflammatory process. 39, 42 These mediators allow crosstalk between adipose tissue and organs such as the liver, which responds by producing hepatokines such as fibroblast growth factor 21, fetuin-A, CRP, TNF-a, and IL-6 ( Fig. 3) . [42] [43] [44] These molecules are released by hepatocytes and directly affect lipid and glucose metabolism in a similar way to adipocytokines, exerting affects in metabolic disease, including NAFLD. 42 Furthermore, some of these immune mediators play dominant roles in development of MetS, such as elevated levels of leptin and decreased levels of adiponectin, both of which are observed in obesity and MetS. 45, 46 Levels of pro-and anti-inflammatory adipocytokines are imbalanced in patients with psoriasis (significantly higher levels of TNF-a, IL-6, leptin, resistin and visfatin, and significantly lower levels of adiponectin) compared with healthy controls. 47 In a study evaluating the prevalence of NAFLD in psoriasis, individuals with both conditions had significantly higher levels of IL-6 and lower serum levels of adiponectin than those with psoriasis alone. 27 In another study, patients with psoriasis and NAFLD had significantly higher leptin, cytokeratin 18 and IL-6 levels and lower adiponectin levels than those without NAFLD. 37 Although the pathophysiology of NAFLD has not been completely elucidated, the 'multiple hit model' describes it as complex, multistep liver injury (Fig. 4) . 6, [48] [49] [50] [51] [52] [53] Insulin resistance -which may, in part, arise from overproduction of proinflammatory cytokines in patients with psoriasis -leads to hepatic accumulation of triglycerides. Subsequent steatosis renders the liver susceptible to further inflammatory insults, which may result in mitochondrial dysfunction, oxidative damage, dysregulated hepatocyte apoptosis, activation of the profibrogenic transforming growth factor-b (TGF-b) pathway, hepatic stellate cell activation and injury caused by adipocytokines and other inflammatory cytokines. Steatosis may also accelerate proinflammatory adipocytokines and systemic inflammation, resulting in greater insulin resistance. An imbalance between creation and disposal of triglycerides subsequently occurs, steatosis transitions to NASH and another imbalance develops between hepatocyte death and regeneration. 54 These steps are further intensified by the presence of psoriasis and accompanying inflammatory processes and altered TNF-a: adiponectin ratio, which promotes liver disease progression. 55 Thus, a vicious cycle of iterative liver damage • PsO + NAFLD (n = 61) vs.
PsO (n = 69)
• Significantly more likely to have MetS, higher CRP concentrations, higher ALT (P < 0Á01) PsO + NAFLD vs. PsO
• More severe PsO (per PASI score; P < 0Á01)
• Frequency of NAFLD greater with PASI score ≥10 vs. <10
• NAFLD: only significant predictor of higher PASI score (P = 0Á038)
Miele et al., • PsO vs. no PsO: significantly higher odds of comorbid liver diseases
Odds of comorbid liver diseases:
• Mild-moderate PsO: 1Á02%;
OR, 1Á714 (95% CI 0Á80-3Á67); P = 0Á1601
• Severe PsO: 10Á85%; OR,
Yang et al. • PsO + NAFLD (n = 58) vs.
PsO (n = 254)
• Significantly more likely to have MetS and diabetes (P < 0Á05)
• PsO + NAFLD vs. PsO • Significantly more severe PsO per PASI scores (P = 0Á02)
• PsO + NAFLD (n = 58) vs.
NAFLD (n = 26)
• Significantly more severe NAFLD (fibrosis, steatosis, NASH, P < 0Á05) 
• Significantly higher frequency of hypertension, high LFT levels, and MetS (P ≤ 0Á01)
• Significantly higher BMI; WC; PASI scores; and serum triglyceride, cholesterol and fasting blood sugar levels (P < 0Á01)
• PASI score, WC, • NAFLD-FS:
À1Á57 AE 1Á4 vs.
À3Á10 AE 1Á5 (P ≤ 0Á0001)
• Advanced liver fibrosis: 7% vs.
0% (P < 0Á001)
• Absence of advanced fibrosis: 55% vs. 86% (P < 0Á001) continues, wherein risk of progression is increased when psoriasis, particularly severe psoriasis, is present. [28] [29] [30] 35, 36 In turn, psoriasis severity may be worsened by reactive oxygen species, CRP, IL-6 and other proinflammatory cytokines released from the damaged liver. 27 Interestingly, some, but not all, patients with psoriasis have NAFLD in the absence of MetS. Furthermore, psoriasis is significantly associated with NAFLD, independently of MetS components or other confounders. 29 In our experience, patients with psoriasis may develop progressive NAFLD even in the absence of MetS or other possible cofactors, such as congenital errors of metabolism, viral hepatitis and hepatotoxic drugs. NAFLD is a genetically complex disease and polymorphisms in key genes can determine susceptibility to NAFLD and disease progression. 16, 41, 50, [56] [57] [58] [59] [60] Several candidate genes have been evaluated with a hypothesis-driven approach. For example, some genes linked to NAFLD are related to lipid metabolism [hepatic lipase and lipin-1 (LPIN1), regulation of triglyceride levels; peroxisome proliferator-activated receptor, glucose and lipid metabolism regulation; microsomal triglyceride transfer protein, phospholipid and triglyceride development; and phosphatidylcholine, hepatic formation and secretion of very-low-density lipoproteins) and fibrogenesis (TGF-b1, angiotensinogen, angiotensin receptors) or encode cytokines/adipocytokines (TNF-a, leptin, adiponectin)]. 16, 57, 61, 62 Vitamin D deficiency has also been implicated in the pathogenesis of psoriasis and NAFLD. 63, 64 In patients with NAFLD, low levels of vitamin D cause activation of Toll-like receptors, which exacerbates hepatic inflammation and vitamin D levels have been correlated with disease severity. 63 Additionally, vitamin D is involved in the regulation of the cutaneous immune system, downregulating the expression of proinflammatory cytokines including TNF-a, IL-6 and IL-8.
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More recently, genome-wide association studies have identified new polymorphisms in candidate genes such as the I148M polymorphism in PNPLA3, 66 a gene involved in lipid metabolism, which plays an important role in susceptibility to progressive NAFLD, 60, 67 and the TM6SF2 polymorphism that increases risk for NAFLD and fibrosis.
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Diagnosis of nonalcoholic fatty liver disease
All patients with psoriasis should be screened for NAFLD as NAFLD is present in 7% of lean individuals and severity of NAFLD is independent of liver enzymes levels. 70, 71 We recommend that liver ultrasound and evaluation of liver enzymes should be performed at the time of psoriasis diagnosis. Generally, patients with NAFLD are asymptomatic; however, when symptoms are present, they are typically nonspecific (fatigue, malaise and right upper quadrant discomfort). Therefore, taking a thorough history (including alcohol consumption, previously or currently prescribed medications, physical activity, weight change, history of MetS or components, dietary habits, viral hepatitis risk and family history of liver disease) and conducting a physical examination [vital signs, weight, waist circumference and body mass index (BMI)] with appropriate laboratory testing [liver function tests (LFTs), hepatitis C antibody, hepatitis B surface antigen, hepatitis B core antibody, fasting glucose, haemoglobin A 1C and cholesterol and lipid panel] are essential in patients with suspected NAFLD based on initial ultrasound and liver enzyme findings and should be conducted by a hepatologist (Table 4) . Serum enzyme [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] levels can be mildly elevated, more often in NASH (AST : ALT > 1) 72 than NAFLD (AST : ALT < 1). Alkaline phosphatase levels may be slightly elevated; gamma-glutamyl transferase (GGT) levels are frequently elevated; and bilirubin and albumin levels are normal. 72, 73 Notably, enzyme abnormalities may occur with certain psoriasis medications (methotrexate, acitretin, ciclosporin, nonsteroidal anti-inflammatory drugs, infliximab and, rarely, etanercept, adalimumab or ustekinumab). [73] [74] [75] With advanced disease, hepatomegaly and tenderness and other signs and symptoms of cirrhosis such as dark urine, jaundice, markedly elevated LFTs, elevated serum bilirubin levels, low serum albumin levels and altered prothrombin time may occur. NASH can progress from cirrhosis to liver failure and, more rarely, to hepatic cancer.
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When NAFLD is suspected, consultation or referral to a hepatologist is recommended. Presumptive diagnosis of NAFLD can be made if serum enzyme elevations are confirmed and other potential causes (hepatotoxic medications, excessive alcohol consumption, hereditary disorders) are ruled out. It should be noted that a diagnosis of NAFLD is possible in the absence of elevated serum enzymes. 72 A definitive diagnosis is made when fat is observed in the liver during diagnostic testing (ultrasound, enhanced computed tomography, magnetic resonance imaging).
The only way to confirm diagnosis of NASH definitively is with liver biopsy. 76 High-risk patients who may be candidates for this procedure are those with obesity (BMI ≥ 28 kg/m 2 ) and diabetes and/or AST : ALT ≥ 0.8.
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Treatment of nonalcoholic fatty liver disease
No specific guidelines exist for the treatment of psoriasis and comorbid NAFLD. However, goals of NAFLD treatment are to prevent or reverse hepatic injury and fibrosis, and treatment guidelines are available from the American Association for the Study of Liver Diseases and European Association for the Study of the Liver. 11, 76 According to the guidelines, pharmacological treatment should be limited to NASH because patients with simple steatosis without presence of fibrosis are at low progression risk.
The first-line approach applied to all patients displaying early signs of NAFLD should include lifestyle modification, minimization of alcohol consumption and treatment of underlying conditions and comorbidities (e.g. diabetes/insulin resistance, hyperlipidaemia, hypertension, sleep apnoea, vitamin D deficiency). Progression to liver fibrosis is correlated with the degree of insulin resistance, making this an important aspect of treatment. 77 Weight loss and increased physical activity/exercise can normalize AST and/or ALT levels, reduce necroinflammation and improve insulin resistance, steatosis and liver histology. Loss of ≥ 5% total body weight resulted in higher rates of steatohepatitis resolution and weight loss of > 7% may provide substantial improvement in steatosis, lobular inflammation, ballooning and disease activity. 78 Several supplements, including vitamin D, vitamin E and omega-3 fatty acids, have shown promise, but evidence is limited. Vitamin D deficiency can contribute to increased inflammation by decreased function of T suppressor cells. 13, 79 A recent randomized clinical trial of vitamin D treatment in NAFLD reported no significant changes in serum levels of liver enzymes. 80 However, a significant decrease in levels of malondialdehyde, a marker of lipid peroxidation, was observed, suggesting that vitamin D could be considered as an adjunctive therapy to attenuate systemic inflammation. Levels of a-tocopherol are decreased in NASH, and studies have demonstrated that vitamin E therapy can improve NASH in patients without diabetes. 81, 82 Although not currently recommended for the specific treatment of NAFLD or NASH, omega-3 fatty acids have reduced liver fat and may be considered as first-line treatment of hypertriglyceridemia in patients with NAFLD in the U.S.A. 11, 83 A meta-analysis of omega-3 fatty acids in NAFLD concluded that they have a beneficial effect on liver fat and levels of GGT and blood lipids; treatment with omega-3 fatty acids may therefore slow progression of NAFLD. 84 Diets high in saturated fats or high fructose corn syrup may cause NAFLD, and minimizing these substances may be beneficial. 85 High intake of coffee or oral supplementation of cysteine-rich whey protein has been demonstrated to reduce hepatic steatosis in NAFLD. 86, 87 A recent meta-analysis did not find any significant association between total caffeine consumption and prevalence of NAFLD, but did report that regular caffeine intake (from coffee only) was significantly associated with reduced hepatic fibrosis in NAFLD. 88 The authors suggested that patients with NAFLD should be encouraged to consume coffee daily. Low levels of folic acid have been observed in patients with NASH and NAFLD; 89 however, a 6-month open-label pilot study that investigated the effects of treatment with folic acid in 10 patients with NASH reported no significant changes in levels of serum aspartate or ALT. 90 Although a healthy diet and increased physical activity/exercise provide the best chance for long-term success and overall benefit, evidence indicates physical activity, particularly prolonged activity sessions (increased by ≥ 60 min or maintained at 150 min per week), provides a significant advantage. 91 Nonbiological and biological treatments have been evaluated in NAFLD; however, no drugs are approved. There are no ongoing trials investigating the treatment of NASH in patients with psoriasis.
The confounders: effect of psoriasis drugs on the liver
Because psoriasis is associated with many comorbidities, choosing appropriate treatment is challenging. A number of psoriasis medications can elevate lipid levels, exacerbate liver disease or be hepatotoxic, necessitating careful consideration for their use in people with psoriasis with hepatic abnormalities. Patients with psoriasis are more likely to experience methotrexate hepatotoxicity than patients with rheumatoid arthritis (RA), probably because of higher rates of NAFLD, dyslipidaemia, obesity and diabetes. 92 Maybury et al. performed a review of eight small observational studies in patients with psoriasis receiving treatment with methotrexate. 93 Overall, their review found no statistically significant risk for developing significant liver fibrosis, but there was an increased risk for any fibrosis and cirrhosis. A larger group of prospectively recruited patients with psoriasis and sequential biopsies are needed to draw causal conclusions. Monitoring of liver chemistry in patients with psoriasis taking methotrexate may help detect liver fibrosis; however, comorbidities such as diabetes may confound results. Elevated levels of amino-terminal propeptide of type III collagen (PIIINP) have been observed in patients with psoriasis who developed liver fibrosis; PIIINP is therefore monitored by some dermatologists but its reliability in identifying liver damage is questionable. 92 Although renal toxicity is of greatest concern with ciclosporin, it can increase lipid levels 94 and possibly worsen NAFLD. Acitretin is associated with abnormal LFTs, hyperlipidaemia and liver disease risk factors, but is rarely associated with liver damage. 95 Because some patients tolerate these systemic treatments, they may be occasionally used in comorbid NAFLD if patients are selected carefully and routinely monitored for liver disease progression. 73, 96, 97 For patients with moderate-to-severe psoriasis and no contraindications, biologics, such as TNF-a inhibitors (etanercept, adalimumab, and infliximab), anti-IL-12 ⁄23 agents (ustekinumab) and anti-17A antibodies (secukinumab and ixekizumab) are appropriate. Patients with psoriasis, MetS and NAFLD were treated with etanercept or psoralen-ultraviolet A (PUVA) over 24 weeks. 77 In patients treated with etanercept, there were significant reductions from baseline in AST : ALT measurements, CRP and fasting insulin levels, and homeostasis model assessment index, and a significant increase in quantitative insulin sensitivity check index values. It was concluded that etanercept could be more effective than PUVA in reducing the risk for hepatic fibrosis by decreasing insulin resistance.
A subsequent study confirmed a partial rebalancing of proand anti-inflammatory cytokines, primarily because of reduced proinflammatory cytokine levels, after etanercept treatment. 47 Because the risk for liver disease progression is directly correlated with insulin resistance and TNF-a plays a role in NAFLD pathogenesis, TNF-a inhibitors may serve a dual function in treating psoriasis and limiting the progression of liver disease. However, some patients receiving etanercept gained significant weight and experienced increased waist-to-hip ratios and BMI, which are independent risk factors for fibrosis. Furthermore, drug-related liver toxicity has been observed in clinical studies of patients with psoriasis treated with infliximab; up to 8% of patients developed markedly elevated levels of AST and ALT. 98 These effects were observed independently of other signs of impaired liver function (e.g. abnormal bilirubin levels). Similar effects have not been reported for adalimumab, although the monitoring of liver enzymes during treatment is recommended. 98 Ustekinumab is another potential treatment option, given that drug-related liver toxicity is mild and uncommon, even in pre-existing liver disease and those who experienced liver-related events with other psoriasis drugs, including TNF-a inhibitors. 74 Finally, the efficacy and safety of IL-17A inhibition by secukinumab or ixekizumab in psoriasis was demonstrated in phase III clinical trials. 99, 100 Importantly, there were no clinically relevant changes in liver biochemical tests reported for secukinumab or ixekizumab. [99] [100] [101] In clinical trials of the phosphodiesterase four inhibitor apremilast, adverse events such as renal and liver toxicity were not observed. 30 Thus, it may be suitable for patients with psoriasis and NAFLD.
Conclusions
Psoriasis and its comorbidities have a negative impact on health, quality of life and overall well-being. Each patient with psoriasis should be screened for NAFLD and other comorbidities. Fatty liver disease often provides an indication of potential underlying diseases, including cardiovascular disease, MetS, diabetes, obstructive sleep apnoea and obesity. Other less-common associations are fatty pancreas, hypothyroidism, colon polyps, elevated uric acid levels, vitamin D deficiency and polycystic ovaries. 102, 103 Furthermore, appropriate steps should be taken to choose suitable treatments and reduce risk for liver disease progression. Counselling patients on diet and lifestyle changes and tailoring treatment to meet each patient's needs is integral to successful outcomes. Large, prospective controlled studies are needed to determine if newer biological treatments can prevent progression of NAFLD in psoriasis.
